Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Shares Outstanding (Weighted Average) (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $796.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.36% to $796.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $796.0 million, a 3.36% increase, with the full-year FY2024 number at $739.6 million, up 12.16% from a year prior.
  • Shares Outstanding (Weighted Average) was $796.0 million for Q3 2025 at Mereo BioPharma, roughly flat from $794.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $796.0 million in Q3 2025 to a low of $623.9 million in Q1 2023.
  • A 3-year average of $719.3 million and a median of $739.6 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 22.55% in 2024, then rose 3.1% in 2025.
  • Mereo BioPharma's Shares Outstanding (Weighted Average) stood at $659.5 million in 2023, then increased by 12.16% to $739.6 million in 2024, then increased by 7.62% to $796.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Shares Outstanding (Weighted Average) are $796.0 million (Q3 2025), $794.0 million (Q2 2025), and $784.3 million (Q1 2025).